[{"arm_notes": "", "treatment_id": null, "treatment_name": "Phase IIa: Experimental group: FINLAY-FR-1A 50 \u00b5g of RBD + adjuvant; 0.5 mL by intramuscular route. Treatment scheme: one dose. Presentation: Vial with single dose.Phase IIb: Experimental group: FINLAY-FR-1A 50 \u00b5g of RBD + adjuvant; 0.5 mL by intramuscular route. Treatment scheme: one dose. Presentation: Vial with single dose. Control group: Placebo group: Placebo with adyuvant; 0.5 mL by intramuscular route. Treatment scheme: one dose. Presentation: Vial with single dose.;Post-Exposure Prophylaxis;Immunogenicity; Vaccine;Immunotherapy; Active;Vaccination;Injections; Intramuscular;Placebos ;Single Dose", "treatment_type": "TODO", "pharmacological_treatment": "TODO"}]

[{"arm_notes": "50 \u03bcg;1", "treatment_id": 513, "treatment_name": "Finlay-fr-1a anti-sars-cov-2 vaccine", "treatment_type": "Protein subunit", "pharmacological_treatment": "Vaccine"}, {"arm_notes": "", "treatment_id": 2187, "treatment_name": "Placebo", "treatment_type": "Placebo", "pharmacological_treatment": "Placebo"}]

[{"arm_notes": "", "treatment_id": null, "treatment_name": "Phase IIa: Experimental group: FINLAY-FR-1A 50 ?g of RBD + adjuvant; 0.5 mL by intramuscular route. Treatment scheme: one dose. Presentation: Vial with single dose. Phase IIb: Experimental group: FINLAY-FR-1A 50 ?g of RBD + adjuvant; 0.5 mL by intramuscular route. Treatment scheme: one dose. Presentation: Vial with single dose. Control group: Placebo group: Placebo with adyuvant; 0.5 mL by intramuscular route. Treatment scheme: one dose. Presentation: Vial with single dose.;Post-Exposure Prophylaxis", "treatment_type": "TODO", "pharmacological_treatment": "TODO"}]